LT3947392T - Izotiazolidino 1,1-dioksidas ir 1,4-butano sultonas, kurių sudėtyje yra rapamicino dariniai ir jų panaudojimas - Google Patents
Izotiazolidino 1,1-dioksidas ir 1,4-butano sultonas, kurių sudėtyje yra rapamicino dariniai ir jų panaudojimasInfo
- Publication number
- LT3947392T LT3947392T LTEPPCT/IB2020/052825T LTIB2020052825T LT3947392T LT 3947392 T LT3947392 T LT 3947392T LT IB2020052825 T LTIB2020052825 T LT IB2020052825T LT 3947392 T LT3947392 T LT 3947392T
- Authority
- LT
- Lithuania
- Prior art keywords
- isothiazolidine
- dioxide
- rapamycin derivatives
- containing rapamycin
- butan
- Prior art date
Links
- XGYCWCIGCYGQFU-UHFFFAOYSA-N 1,2-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCCN1 XGYCWCIGCYGQFU-UHFFFAOYSA-N 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962824190P | 2019-03-26 | 2019-03-26 | |
PCT/IB2020/052825 WO2020194209A1 (en) | 2019-03-26 | 2020-03-25 | Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3947392T true LT3947392T (lt) | 2024-05-27 |
Family
ID=70190042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/IB2020/052825T LT3947392T (lt) | 2019-03-26 | 2020-03-25 | Izotiazolidino 1,1-dioksidas ir 1,4-butano sultonas, kurių sudėtyje yra rapamicino dariniai ir jų panaudojimas |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220202787A1 (lt) |
EP (1) | EP3947392B1 (lt) |
JP (1) | JP7461369B2 (lt) |
KR (1) | KR20210142689A (lt) |
CN (1) | CN113614090A (lt) |
AU (1) | AU2020250026B2 (lt) |
BR (1) | BR112021018692A2 (lt) |
CA (1) | CA3134653A1 (lt) |
DK (1) | DK3947392T3 (lt) |
FI (1) | FI3947392T3 (lt) |
LT (1) | LT3947392T (lt) |
MX (1) | MX2021011376A (lt) |
PT (1) | PT3947392T (lt) |
WO (1) | WO2020194209A1 (lt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3103282A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
IL293549A (en) | 2019-12-05 | 2022-08-01 | Anakuria Therapeutics Inc | Rapamycin analogs and their uses |
JP2023028473A (ja) * | 2021-08-19 | 2023-03-03 | 日本マイクロバイオファーマ株式会社 | エベロリムスの製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
CA2257803C (en) | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
AU783158B2 (en) * | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
US20090023768A1 (en) * | 2006-02-24 | 2009-01-22 | Novartis Ag | Rapamycin derivatives for treating neuroblastoma |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
WO2017044720A1 (en) * | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
-
2020
- 2020-03-25 WO PCT/IB2020/052825 patent/WO2020194209A1/en unknown
- 2020-03-25 FI FIEP20717312.1T patent/FI3947392T3/fi active
- 2020-03-25 BR BR112021018692A patent/BR112021018692A2/pt unknown
- 2020-03-25 CN CN202080022154.4A patent/CN113614090A/zh active Pending
- 2020-03-25 EP EP20717312.1A patent/EP3947392B1/en active Active
- 2020-03-25 AU AU2020250026A patent/AU2020250026B2/en active Active
- 2020-03-25 US US17/442,733 patent/US20220202787A1/en active Pending
- 2020-03-25 MX MX2021011376A patent/MX2021011376A/es unknown
- 2020-03-25 LT LTEPPCT/IB2020/052825T patent/LT3947392T/lt unknown
- 2020-03-25 JP JP2021557231A patent/JP7461369B2/ja active Active
- 2020-03-25 KR KR1020217033691A patent/KR20210142689A/ko unknown
- 2020-03-25 PT PT207173121T patent/PT3947392T/pt unknown
- 2020-03-25 CA CA3134653A patent/CA3134653A1/en active Pending
- 2020-03-25 DK DK20717312.1T patent/DK3947392T3/da active
Also Published As
Publication number | Publication date |
---|---|
AU2020250026B2 (en) | 2023-08-10 |
JP7461369B2 (ja) | 2024-04-03 |
EP3947392B1 (en) | 2024-02-28 |
AU2020250026A1 (en) | 2021-09-23 |
JP2022527270A (ja) | 2022-06-01 |
KR20210142689A (ko) | 2021-11-25 |
US20220202787A1 (en) | 2022-06-30 |
EP3947392A1 (en) | 2022-02-09 |
PT3947392T (pt) | 2024-05-14 |
CN113614090A (zh) | 2021-11-05 |
MX2021011376A (es) | 2021-10-13 |
DK3947392T3 (da) | 2024-04-29 |
WO2020194209A1 (en) | 2020-10-01 |
FI3947392T3 (fi) | 2024-05-08 |
BR112021018692A2 (pt) | 2021-11-23 |
CA3134653A1 (en) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI3947392T3 (fi) | Isotiatsolidiini-1,1-dioksidia ja 1,4-butaanisultonia sisältäviä rapamysiinijohdannaisia ja niiden käyttöjä | |
SG11202006906XA (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
GB201721185D0 (en) | Sulphonyl urea derivatives | |
EP3661918A4 (en) | ANALOGUES OF 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE | |
EP3931194C0 (en) | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR-CONTAINING SUBSTITUENTS | |
FI3986890T3 (fi) | Bentsisoksatsolisulfonamidijohdannaisia | |
EP3656770A3 (en) | Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocycles | |
IL267899A (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors | |
MX2018009459A (es) | Derivado de sulfonamida y composicion farmaceutica que contiene el mismo. | |
IL276952A (en) | History of 4,2-diaminoquinazolines and their medicinal uses | |
ZA202204675B (en) | New methylquinazolinone derivatives | |
EP4037670A4 (en) | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | |
EP3660019C0 (en) | 7H-PYRAZOLO[3,4-D]TRIAZINE-2-OXIDES AS EXPLOSIVES | |
SI1963295T1 (sl) | Derivati 3,6-dihidro-2-okso-6h-(1,3,4)tiadiazina | |
IL289197A (en) | History of 2-hydroxycycloalkane-1-carbamoyl | |
GB2606804B (en) | Benzenesulfonamide derivatives and uses thereof | |
ZA201906888B (en) | Amide derivatives as nav1.7 and nav1.8 blockers | |
IL279939A (en) | History of thiadiazine | |
ZA202106024B (en) | Heterocyclic derivatives | |
IL278770A (en) | The history of thiofan, their preparation and their use | |
IL290815A (en) | History of alpha-d-galactopyranoside | |
IL287521A (en) | History of 3-amino-h4-benzo[e][4,2,1]thiadiazine 1,1-dioxide as mrgx2 inhibitors | |
EP3715344A4 (en) | 1,4-BENZODIAZAPINE-2-ON DERIVATIVES AND THEIR USES | |
IL289677A (en) | camptothecin derivatives with a disulfide group and with piperazine | |
IL284843A (en) | Carbamate derivatives and their uses |